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ABSTRACT 
Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant. Deflazacort are commonly Prescribed for the patient 
in disease condition such as Inflammatory Bowel Disease (IBD) ulcerative colitis (UC) and Crohn’s disease (CD). Delivery of drug substances 
to the ileo-colonic region may be an essential element of successful drug treatment (improved efficacy or reduced systemic toxicity) in 
topical treatment of the colon. The colon targeted drug delivery can also be used for effective treatment of diseases. This may improve 
efficacy of drug treatment, decrease in dose to be administered, improved drug utilization. It is a promising site for a drug which is unstable 
or poorly absorbed. Currently available formulation of deflazacort is conventional solid dosage form (6, 12, 18 & 30 mg tablets). Dosage form 
require frequent dose of administration due to its short half life of 1.1-1.9 hrs. So, present study is aimed to develop an colon targeted 
sustained release dosage form has been developed as these releases the drug slowly into the ileo- colonic region and maintain constant drug 
concentration  in the serum for longer period of time.  
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INTRODUCTION 
Oral controlled release dosage forms have been developed 
over the past three decades due to their considerable 
therapeutic advantages such as ease of administration, 
patient compliance and flexibility in formulation. 
Microsphere carrier systems made from the naturally 
occurring biodegradable polymers have attracted 
considerable attention for several years in sustained drug 
delivery. Recently, dosage forms that can precisely control 
the release rates and target drugs to a specific body site 
have made an enormous impact in the formulation and 
development of novel drug delivery systems 1-3. They have 
varied applications and are prepared using assorted 
polymers4. However, the success of these microspheres is 
limited owing to their short residence time at the site of 
absorption. It would, therefore, be advantageous to have 
means for providing an intimate contact of the drug 
delivery system with the absorbing membranes5 Ongoing 
research in the area of oral delivery of drugs, a discipline 
which has basked in the spotlight of pharmaceutical 
sciences for the past 70 years, has led to improved and 
profound insights into the physiology, biology and physical 
chemistry (pharmacokinetics, partitioning phenomenon) 
of organs, compartments, cells, membranes, cellular 
organelles and functional proteins (e.g. transporters) 
associated with absorption processes of drugs in the 
gastrointestinal tract (GIT). Deflazacort is a glucocorticoid 
used as an anti-inflammatory and immunosuppressant. 
Deflazacort are commonly Prescribed for the patient in 
disease condition such as Inflammatory Bowel Disease 
(IBD) ulcerative colitis (UC) and Crohn’s disease (CD). The 
colon targeted drug delivery can also be used for effective 
treatment of diseases. This may improve efficacy of drug 
treatment, decrease in dose to be administered, improved 
drug utilization. It is a promising site for a drug which is 
unstable or poorly absorbed.6, 7  
MATERIALS & METHODS 
Method of Preparation of Core Tablet8 
 Core tablet was prepared by Direct Compression 
method. 
 Weighed accurate quantity of drug (Deflazacort) with 
polymers (HPMC K4M, Methocel K15M and Ethyl 
cellulose,) and other excipient (MCC PH-102) & talc. 
 Then above directly compressible ingredient was 
passed through sieve no. 40# and mixed properly. 
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 Then the magnesium stearate and talc (100# passed) 
were mixed along the powder. Tablets were prepared 
by using eight station rotary tablet press. 
Procedure for Tablet Coating9: 
 The tablets were dip-coated with different concentration of 
Eudragit S100 dispersion in a mixture of acetone: 
isopropyl alcohol (1:1) containing 1.25% polyethylene 
glycol plasticizer. The weighed core tablets were dipped 
into coating solutions by holding with forceps and after 
dipping placed on a glass plate .The tablet were dried 
initially at room temperature for 15 min and then in a hot 
air oven at 60°C for 30 minutes. 
 
Table 1: Various formulation of Deflazacort Tablet 
Ingredient 
(mg.) 
B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 
Deflazacort 12.30 12.30 12.30 12.30 12.30 12.30 12.30 12.30 12.30 12.30 12.30 
HPMC K4M 20 40 60 - - - 20 - 20 20 20 
HPMCK15M - - - 20 30 40 - 20 - - - 
Ethyl 
cellulose 
- - - - - - 8 8 - - - 
MCC PH 102 162.70 142.70 122.70 162.70 152.7 142.7 154.7 154.7 162.7 162.7 162.70 
Talc 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Magnesium 
Stearate 
2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Total wt. 
(mg.) 
200 200 200 200 200 200 200 200 200 200 200 
   
Table 2: Ingredients of Coating Solution 
Coating solution Composition 
 I II III 
Eudragit S100 8% 10% 12% 
PEG 400 1.25% 1.25% 1.25% 
Acetone: Isopropyl alcohol (1:1) 20 ml 20 ml 20 ml 
 
RESULT & DISCUSSION 
Table: 03 Evaluation Parameters for (Uncoated Tablet) F1-F9 Optimized formulation 
Batch 
Code 
Hardness 
(kg/cm2) 
Thickness 
(mm) 
% Friability Drug Content 
Uniformity (%) 
Average Weight of 
Tablet (mg) 
F1 5.83±0.5 3.1±0.2 0.55 96.58 202±2.00 
F2 5.24±0.5 3.0±0.2 0.61 95.51 200±2.16 
F3 5.05±0.5 3.0±0.2 0.65 96.78 204.23±1.77 
F4 5.64±0.5 3.1±0.3 0.59 94.36 202.15±2.20 
F5 6.01±0.5 3.2±0.3 0.63 95.72 204±1.20 
F6 5.93±0.5 3.1±0.3 0.66 97.34 200±2.05 
F7 5.32±0.5 3.1±0.2 0.7 94.56 203.25±1.47 
F8 6.25±0.5 3.0±0.3 0.74 96.89 201.14±0.51 
F9 6.06±0.5 3.1±0.2 0.78 95.62 200.16±0.53 
 
Post- Compression parameter for uncoated tablet is tested 
for hardness, thickness, friability, drug content, weight 
variation. Hardness of the prepared tablets was found in 
range of 5.5-6.5 kg/cm2. Drug content is come under 90-
110% in range as specified in pharmacopoeia10. All the 
tablet formulations showed acceptable pharmacopoeia 
limits and complied with the in-house specifications for 
thickness, weight variation, drug content, hardness, and 
friability.11, 12  
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Table 4: Evaluation Parameters for Factorial Batches of (Coated Tablets) F1-F9 Optimized formulation 
Batch Code Hardness 
(kg/cm2) 
Thickness 
(mm) 
Average Weight of 
Tablet (mg) 
% Weight Gain %Swelling study 
F1 6.73±0.5 4.14±0.2 218±1.24 9.19±0.52 180 
F2 6.74±0.5 4.05±0.2 217±2.16 8.91±0.54 210 
F3 6.64±0.5 4.17±0.2 219.25±0.82 9.14±0.18 230 
F4 6.84±0.5 4.18±0.3 218.35±1.75 9.52±0.48 165 
F5 6.66±0.5 4.21±0.3 217.25±0.42 9.18±0.57 198 
F6 6.7±0.5 4.2±0.3 218.14±2.00 9.64±0.53 222 
F7 6.5±0.5 4.15±0.2 217.23±1.77 9.84±0.62 152 
F8 6.49±0.5 4.2±0.3 218.15±2.20 9.58±0.48 185 
F9 6.58±0.5 4.12±0.3 218.15±2.20 9.95±0.48 195 
 
From trial batches B1-B8 in Vitro drug release studies are 
shown in table no.5. Batch B1-B3 in which HPMC K4M are 
used as hydrophilic polymer as it shows it release drug 
initially before 10 hours. HPMC K15M is also used in which 
batch B4-B6 shows 80-88% drug release. So, it’s better to 
prepare combination batches B7-B8 in which HPMC K4M 
combined with hydrophobic polymer such as ethyl 
cellulose to retard the drug release as a result batch B7 
shows 93.13% drug release in 10 hours.13-14 
 
Table: 05 % Cumulative Drug Release profile of various Formulations 
Time 
(Hrs.) 
% Cumulative Drug Release 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 
1 0 0 0 0 0 0 0 0 0 
2 0 0 0 0 0 0 0 0 0 
3 0 0 0 0 0 0 0 0 0 
4 0 0 0 0 0 0 0 0 0 
5 0 0 0 0 0 0 0 0 0 
6 28.75 21.38 17.58 26.91 19.56 16.67 24.76 18.81 15.86 
7 43.02 32.35 29.36 37.7 32.44 25.76 33.15 30.96 22.63 
8 52.12 44.65 42.3 44.43 43.64 36.33 41.52 42.05 26.11 
9 66.58 53.78 51.66 53.52 51.25 44.54 49.6 51.28 37.26 
10 71.22 60.65 59.7 60.26 62.23 55.12 57.63 60.25 45.26 
11 77.36 68.23 67.68 68.32 70.63 63.45 65.22 66.52 51.88 
12 82.05 74.52 75.74 73.79 76.95 72.7 74.52 71.23 59.89 
13 86.54 82.74 81.85 80.74 82.5 80.52 82.15 78.52 64.76 
14 91.04 88.92 87.32 86.26 88.74 86.44 87.32 84.23 76.26 
15 95.12 94.72 93.16 94.26 92.48 90.56 91.13 88.12 85.57 
 
CONCLUSION 
Deflazacort is a glucocorticoid. Its anti-inflammatory and 
immunosuppressive effects are used in treating various 
diseases and are comparable to other anti-inflammatory 
steroids. 
A 32 full factorial design was used to check effect of HPMC 
K4M and Ethyl cellulose on tablet characteristics. %CDR at 
6 hours (Q6) and %CDR at 6 hours (Q15) selected as 
dependent variables. Multiple linear regression analysis 
and ANOVA results showed that selected factors were 
significant as p value was lower than 0.05. Full model and 
reduced model for individual factor were prepared and 
evolved. Check point batches was prepared and the results 
of actual value were comparable with predicted value. 
The release profile of the selected formulation was found 
to follow Higuchi model (r2 =0.9984). Further, selected 
formulation (Batch F4) was subjected to short term 
accelerated stability study at 60±2°C / 75±5 % RH after 
packing in Aluminium foil;  similarity factor was found to 
be 85%,results revealed that applied storage conditions 
showed no significant effect on drug content, hardness  in 
vitro drug release profile after storage for two weeks. 
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